This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
by Zacks Equity Research
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Philips' (PHG) Launches a Range of New Products at EuroPCR 2022
by Zacks Equity Research
Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aclaris Therapeutics (ACRS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?
by Zacks Equity Research
Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
by Zacks Equity Research
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -111.11% and 20.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
by Zacks Equity Research
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 13.79% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate
by Zacks Equity Research
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.
Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?